| Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine (NCT05453487) | China National Biotec Group Company Limited | 2022-07-21 |
| Social Media as an Information, Education and Communication Tool for Rabies Prevention: An Interventional Study (NCT05702008) | Maulana Azad Medical College | 2022-07-01 |
| A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG (NCT04270838) | University of Oxford | 2022-02-17 |
| Immunity Persistence After Abridged Intradermal Rabies PEP (NCT04829630) | Institut Pasteur | 2021-10-20 |
| A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety (NCT04644484) | Synermore Biologics (Suzhou) Co., Ltd. | 2020-09-23 |
| Safety and Immunogenicity of Purified Verocell Rabies Vaccine PVRV Administered Intramuscularly and Intradermally (NCT06433440) | University of Peshawar | 2020-07-01 |
| Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and Intradermally (NCT05937113) | Vietnam Military Medical University | 2020-06-13 |
| Immunological Tolerance After Frequent Rabies Booster Vaccinations (NCT03729102) | Queen Saovabha Memorial Institute | 2020-06-04 |
| Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG (NCT04162600) | University of Oxford | 2020-01-02 |
| Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine (NCT05547815) | Changchun Zhuoyi Biological Co., Ltd | 2019-11-11 |
| Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults (NCT04127786) | Sanofi Pasteur, a Sanofi Company | 2019-10-21 |
| Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects (NCT04019444) | National Institute of Allergy and Infectious Diseases (NIAID) | 2019-09-19 |
| Phone Text Message Reminders on Compliance With Human Rabies Post Exposure Prophylaxis Project (NCT05350735) | Washington State University | 2018-10-01 |
| Immunity Duration of Rabies Vaccine and Booster Dose Effects at 10 Years Post-primary Vaccination (NCT03774628) | Jiangsu Province Centers for Disease Control and Prevention | 2018-08-01 |
| Effect of ERIG Injection on Day 7 After First Dose of Rabies Vaccination to Rabies Immune Response (NCT03524417) | Queen Saovabha Memorial Institute | 2018-04-30 |
| Immune Responses and Immunological Tolerance After Rabies Booster Vaccination in HIV-infected Adults (NCT03228069) | Queen Saovabha Memorial Institute | 2017-08-01 |
| Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. (NCT02564471) | State University of New York - Upstate Medical University | 2016-11-11 |
| Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults (NCT02547727) | Queen Saovabha Memorial Institute | 2016-02-01 |
| Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen (NCT02956421) | Yisheng Biopharma (Singapore) Pte. Ltd. | 2016-02-01 |
| A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis. (NCT02545517) | GlaxoSmithKline | 2015-10-05 |
| Safety Study of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered Intramuscularly (NCT02729168) | Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products | 2015-10-01 |
| Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis (NCT02374814) | State University of New York - Upstate Medical University | 2015-03-24 |
| Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients (NCT03093545) | Mahidol University | 2015-03-01 |
| Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant (NCT02657161) | Yisheng Biopharma (Singapore) Pte. Ltd. | 2015-02-01 |
| Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects. (NCT02559921) | Beijing Chaoyang District Centre for Disease Control and Prevention | 2014-12-01 |
| The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans (NCT02281396) | Beijing Center for Disease Control and Prevention | 2014-11-01 |
| Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults (NCT02238756) | CureVac | 2014-09-01 |
| An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human) (NCT02139657) | Grifols Therapeutics LLC | 2014-03-01 |
| RNActive® Rabies Vaccine (CV7201) in Healthy Adults (NCT02241135) | CureVac | 2013-10-01 |
| Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen (NCT01877395) | Sanofi Pasteur, a Sanofi Company | 2013-06-01 |
| Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects (NCT02040090) | Kamada, Ltd. | 2013-04-01 |
| Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use (NCT01784874) | Sanofi Pasteur, a Sanofi Company | 2013-02-01 |
| A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults (NCT01680016) | Novartis Vaccines | 2012-09-01 |
| A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects (NCT02491541) | Jiangsu Province Centers for Disease Control and Prevention | 2012-08-01 |
| Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects (NCT01662440) | Novartis Vaccines | 2012-08-01 |
| Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen (NCT01622062) | Sanofi Pasteur, a Sanofi Company | 2012-06-29 |
| Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response (NCT01610362) | Queen Saovabha Memorial Institute | 2012-06-01 |
| Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults (NCT01228383) | Crucell Holland BV | 2011-12-01 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults (NCT01466387) | Novartis | 2011-11-01 |
| Simplifying the Rabies Pre-exposure Vaccination (NCT01388985) | Institute of Tropical Medicine, Belgium | 2011-10-01 |
| Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules (NCT01365494) | Novartis Vaccines | 2011-07-01 |
| Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine (NCT01339312) | Sanofi Pasteur, a Sanofi Company | 2011-04-01 |
| Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination (NCT01286493) | Queen Saovabha Memorial Institute | 2011-02-01 |
| Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG (NCT01137045) | Queen Saovabha Memorial Institute | 2010-06-01 |
| Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose (NCT01173302) | Peking University People's Hospital | 2010-05-01 |
| Single Center, Open Label, Follow up Study in Subjects Who Previously Received Rabies Vaccine as Simulated Post-Exposure Regimen (NCT01067079) | Novartis Vaccines | 2010-01-01 |
| Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults (NCT00948272) | Sanofi Pasteur, a Sanofi Company | 2009-07-01 |
| Rabies Immune Plasma Booster Study (NCT01063140) | CSL Behring | 2009-01-01 |
| Safety and Immunogenicity (Non-inferiority) of a Purified Chick Embryo Cell Vaccine Vaccine Administered in Two Different Schedules (Conventional Versus Abbreviated Schedule) (NCT00825305) | Novartis Vaccines | 2008-11-01 |
| Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents (NCT00708084) | Crucell Holland BV | 2008-05-01 |
| A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects (NCT00656097) | Crucell Holland BV | 2008-03-01 |
| Immunogenicity and Safety of Verorab™ in Indian Population (NCT00260351) | Sanofi Pasteur, a Sanofi Company | 2004-12-01 |
| Rabies Immunization Concomitant With JEV in Children (NCT00703521) | Mahidol University | 2002-08-01 |
| Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers (NCT00694460) | Novartis | 2002-08-01 |
| An Expanded Access Program for SYN023 in Rabies Treatment (NCT07706907) | Synermore Biologics (Suzhou) Co., Ltd. | |